Amgen hit by Novartis drug trial setback
Amgen's stock suffered a sharp decline after a clinical trial setback for a similar heart disease drug from Novartis cast doubt on the entire drug class.
WSJ WHAT'S NEWS CHANGED ITS VIEW
BULLISH FOR 4 WEEKS, THEN THE TURNKeep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.